SNMMI

Reminder to come by Plus Therapeutics at the SNMMI 2024 Annual Meeting in Toronto at Booth #1948

Learn about the latest ReSPECT-LM Clinical Trial data for Leptomeningeal Metastases and view our newest poster in the poster hall

Two accepted abstracts titled:

“Rhenium (186Re) obisbemeda (186RNL) in leptomeningeal metastases (LM) Phase 1/2A Dose Escalation Trial: Update of Initial Safety and Feasibility through Cohorts 1-4”

“Radiation Absorbed Dose to Spinal Cord: Therapy of Leptomeningeal Metastasis Using Beta-Emission Radiopharmaceuticals”

Posters will be available on https://ir.plustherapeutics.com/ after the conference.